Principal Financial Group Inc. boosted its holdings in Glaukos Co. (NYSE:GKOS – Get Rating) by 0.2% in the 4th quarter, Holdings Channel reports. The firm owned 310,099 shares of the medical instruments supplier’s stock after purchasing an additional 672 shares during the period. Principal Financial Group Inc.’s holdings in Glaukos were worth $13,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lord Abbett & CO. LLC purchased a new position in Glaukos during the 3rd quarter worth $61,056,000. Fred Alger Management LLC increased its holdings in shares of Glaukos by 34.3% in the 3rd quarter. Fred Alger Management LLC now owns 1,402,110 shares of the medical instruments supplier’s stock valued at $74,648,000 after purchasing an additional 358,360 shares in the last quarter. Polar Asset Management Partners Inc. increased its holdings in shares of Glaukos by 121.4% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 593,508 shares of the medical instruments supplier’s stock valued at $31,598,000 after purchasing an additional 325,400 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Glaukos by 39.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 530,668 shares of the medical instruments supplier’s stock valued at $28,253,000 after purchasing an additional 149,548 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Glaukos by 71.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 323,467 shares of the medical instruments supplier’s stock valued at $14,692,000 after purchasing an additional 134,989 shares in the last quarter. Hedge funds and other institutional investors own 92.17% of the company’s stock.
Glaukos Price Performance
Shares of NYSE GKOS opened at $56.66 on Thursday. Glaukos Co. has a 52 week low of $38.60 and a 52 week high of $61.01. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -19.40 and a beta of 1.24. The company’s 50-day moving average price is $51.46 and its 200 day moving average price is $48.80. The company has a current ratio of 6.67, a quick ratio of 6.02 and a debt-to-equity ratio of 0.70.
Insiders Place Their Bets
In other Glaukos news, CEO Thomas William Burns sold 11,662 shares of the firm’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $60.17, for a total transaction of $701,702.54. Following the sale, the chief executive officer now directly owns 673,963 shares of the company’s stock, valued at approximately $40,552,353.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 15,373 shares of company stock valued at $924,400 in the last ninety days. Insiders own 7.80% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on GKOS shares. 888 reiterated a “maintains” rating on shares of Glaukos in a report on Thursday, May 4th. JPMorgan Chase & Co. increased their price target on shares of Glaukos from $42.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, February 23rd. Needham & Company LLC increased their price target on shares of Glaukos from $57.00 to $58.00 in a report on Thursday, May 4th. William Blair reiterated an “outperform” rating on shares of Glaukos in a report on Wednesday, February 22nd. Finally, Citigroup increased their price objective on shares of Glaukos from $57.00 to $59.00 and gave the company a “buy” rating in a research note on Thursday, February 23rd. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $56.13.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS – Get Rating).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.